Company
Sensorium Therapeutics
Sensorium is a clinical-stage biotech developing first-in-class CNS therapies, guided by human biology and nature’s neuroactive patterns, to relieve suffering and restore wellbeing.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Sensorium Therapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
Sensorium Therapeutics is a clinical stage biotechnology company developing brain and mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to help people thrive.
Funding snapshot
- Total raised
- $60.5MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $25M2025-08-19
Funding rounds
- Round, 2025
- $25M2025-08-19, Company stated
- Round, 2025
- $26.8M2025-01-28, SEC form D sold, 19 investors
- Round, 2022
- $24.7M2022-09-19, SEC form D sold, 64 investors
- Round, 2021
- $9M2021-07-08, SEC form D sold, 47 investors
About the company
- Status notes
- Lead program in social anxiety disorder in Phase 1 trial
Loading relationship preview